Blueprint Medicines Corp. Gets High Ratings from Guru Model

Blueprint Medicines Corp. (BPMC) achieves a 66% rating from a growth model, indicating solid investment potential. The stock shows strengths in cash flow but has areas needing improvement, particularly in return on assets.

Date: 13-02-2025

AI Rating: 6

Analysis of Blueprint Medicines Corp.

Blueprint Medicines Corp (BPMC) received a 66% rating based on the P/B Growth Investor model by Partha Mohanram, which suggests good investment potential. A score above 80% usually indicates interest, while a score above 90% suggests strong interest. Thus, BPMC's score places it in a moderately favorable position.

The report specifically addresses criteria such as:

Book/Market Ratio: PASS
Return on Assets: FAIL
Cash Flow from Operations to Assets: PASS
Cash Flow from Operations to Assets vs. Return on Assets: PASS
Return on Assets Variance: FAIL
Sales Variance: FAIL
Advertising to Assets: FAIL
Capital Expenditures to Assets: PASS
Research and Development to Assets: PASS

This evaluation shows that while BPMC demonstrates adequate strength in its book-to-market ratio and cash flow metrics, it fails in critical areas such as return on assets and sales variance. These weaknesses could raise concerns for potential investors, as the ability to convert assets into profit is crucial for growth companies. In summary, Blueprint Medicines Corp shows decent growth potential but requires improvements in certain financial metrics to become a more attractive investment.

Stocks: BPMC